Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU)

被引：2
|
作者：
Moulard, Odile [1 ]
Mehta, Jyotsna [2 ]
Olivares, Robert [1 ]
Iqbal, Usman [2 ]
Mesa, Ruben A. [3 ]
机构：
[1] Sanofi, Global Evidence & Value Dev, Chilly Mazarin, France
[2] Sanofi, Global Evidence & Value Dev, Cambridge, MA USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1744.1744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1744
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)
    Mehta, J.
    Le-Ruyet, O.
    Fryzek, J.
    Iqbal, S. U.
    Mesa, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S323 - S324
  • [2] Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
    Moulard, Odile
    Mehta, Jyotsna
    Fryzek, Jon
    Olivares, Robert
    Iqbal, Usman
    Mesa, Ruben A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (04) : 289 - 297
  • [3] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [4] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [5] Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Silver, Richard T.
    Kiladjian, Jean-Jacques
    Hasselbalch, Hans Carl
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 49 - 58
  • [6] A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Datoguia, Tarcila Santos
    Goncalves, Giulliana A. R.
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [7] Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Puga, Renato D.
    Alves Paiva, Raquel de Melo
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [8] Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)
    Brodsky, I
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01): : 105 - 106
  • [9] POLYCYTHEMIA VERA (PV) BUT NOT ESSENTIAL THROMBOCYTHEMIA (ET) REDUCES THE LIFE EXPECTANCY IN ELDERLY
    Tezza, F.
    Ruzzon, E.
    Zambon, S.
    Manzato, E.
    Fabris, F.
    Randi, M. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 359 - 359
  • [10] UNUSUAL VEIN THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)
    Randi, M. L.
    Scapin, M.
    Tezza, E.
    Carideo, N.
    Bertozzi, I.
    Duner, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 60 - 60
12345